This site is intended for healthcare professionals
CDK 4/6 hero
CDK4/6 inhibitor selection in metastatic breast cancer

CDK4/6 inhibitor selection

Read time: 60 mins
Last updated:13th Apr 2022
Published:22nd Apr 2021

Abemaciclib, palbociclib and ribociclib are three CDK4/6 inhibitors approved for the treatment of HR+/HER2− locally advanced or metastatic breast cancer, but how do they compare and how will you decide on which CDK4/6 inhibitor to select for your breast cancer patient?

Abemaciclib, palbociclib and ribociclib are three cyclin dependent kinase (CDK)4/6 inhibitors that are US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved for the treatment of hormone receptor positive/human epidermal growth factor 2 negative (HR+/HER2−) locally advanced or metastatic breast cancer1-6. Abemaciclib is also FDA approved as a monotherapy for HR+/HER2− advanced breast cancer in patients who have progressed following endocrine therapy and prior chemotherapy treatment5. Both the FDA and EMA have also extended the indication for abemaciclib to include adjuvant therapy for high-risk early breast cancer4,5.

Access this full range of information on CDK4/6 inhibitor selection in breast cancer by registering for a free Medthority account today, or log in to your existing account. 

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Welcome: